crisaborole sold brand name eucrisa among others nonsteroidal topical medication used treatment mildtomoderate atopic dermatitis eczema adults common side effects reactions application site including burning crisaborole phosphodiesterase inhibitor although specific mechanism action atopic dermatitis site application crisaborole may cause burning stinging rarely may allergic us crisaborole indicated topical treatment mild moderate atopic dermatitis people three months age eu crisaborole authorized treatment mild moderate atopic dermatitis people two years age older body surface area bsa crisaborole inhibitor mainly acting phosphodiesterase causes chemically crisaborole inhibition appears suppress release tumor necrosis factor alpha tnfÎ± cytokines proteins believed involved immune response people atopic dermatitis produce high levels proteins called cytokines cause inflammation skin seen crisaborole blocks release certain cytokines involved inflammation process tumor necrosis factor alpha interleukins interferon blocking release crisaborole expected ease inflammation therefore relieve symptoms crisaborole chemical name member class benzoxaboroles characterized presence boronic acid hemiester phenolic ether crisaborole crystallizes two polymorphs differ conformation oxaborole ring cocrystal prepared studied xray crisaborole developed anacor pharmaceuticals topical treatment preclinical clinical development crisaborole called drug assumed potential blockbuster pfizer acquired anacor however drug commercially successful reaching million sales million sales crisaborole approved use united states december use canada june safety efficacy crisaborole established two placebocontrolled trials total participants ranging age two years age years age mild moderate atopic trials participants received treatment either crisaborole placebo twice daily neither participants health care providers knew treatment given trials overall participants receiving crisaborole achieved greater response clear almost clear skin days trials conducted crisaborole approved treatment mild moderate atopic dermatitis european union rapidly withdrawn european market march february httpsenwikipediaorgwikicrisaborole